MX2020003748A - Vectores adenovirales con dos casetes de expresion que codifican proteinas antigenicas del vsr o fragmentos de las mismas. - Google Patents
Vectores adenovirales con dos casetes de expresion que codifican proteinas antigenicas del vsr o fragmentos de las mismas.Info
- Publication number
- MX2020003748A MX2020003748A MX2020003748A MX2020003748A MX2020003748A MX 2020003748 A MX2020003748 A MX 2020003748A MX 2020003748 A MX2020003748 A MX 2020003748A MX 2020003748 A MX2020003748 A MX 2020003748A MX 2020003748 A MX2020003748 A MX 2020003748A
- Authority
- MX
- Mexico
- Prior art keywords
- fragments
- expression cassettes
- adenoviral vectors
- antigenic proteins
- cassettes encoding
- Prior art date
Links
- 230000000890 antigenic effect Effects 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 239000013598 vector Substances 0.000 title abstract 2
- 108700019146 Transgenes Proteins 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572951P | 2017-10-16 | 2017-10-16 | |
| PCT/EP2018/078212 WO2019076882A1 (en) | 2017-10-16 | 2018-10-16 | ADENOVIRAL VECTORS COMPRISING TWO EXPRESSION CASSETTES ENCODING RSV ANTIGENIC PROTEINS OR FRAGMENTS THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003748A true MX2020003748A (es) | 2020-11-06 |
Family
ID=63896162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003748A MX2020003748A (es) | 2017-10-16 | 2018-10-16 | Vectores adenovirales con dos casetes de expresion que codifican proteinas antigenicas del vsr o fragmentos de las mismas. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11859199B2 (enExample) |
| EP (1) | EP3697919A1 (enExample) |
| JP (1) | JP2020537526A (enExample) |
| CN (1) | CN111527213A (enExample) |
| BR (1) | BR112020007008A2 (enExample) |
| CA (1) | CA3079048A1 (enExample) |
| MX (1) | MX2020003748A (enExample) |
| WO (1) | WO2019076882A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022007774A1 (zh) * | 2020-07-06 | 2022-01-13 | 嘉兴安宇生物科技有限公司 | 一种新型黑猩猩腺病毒载体及其构建方法和应用 |
| WO2022102894A1 (ko) * | 2020-11-10 | 2022-05-19 | 주식회사 바이오리더스 | 코로나바이러스의 스파이크 단백질 및 뉴클레오캡시드 단백질을 동시발현하는 복제불능 아데노바이러스를 이용한 코로나바이러스 백신 |
| KR102399308B1 (ko) * | 2020-11-10 | 2022-05-20 | 주식회사 비엘 | 코로나바이러스의 스파이크 단백질 및 뉴클레오캡시드 단백질을 동시발현하는 복제불능 아데노바이러스를 이용한 코로나바이러스 백신 |
| KR102882279B1 (ko) * | 2022-05-09 | 2025-11-10 | 주식회사 모아라이프플러스 | 코로나바이러스의 스파이크 단백질, 뉴클레오캡시드 단백질 및 PgsA 단백질을 동시발현하는 복제불능 아데노바이러스를 이용한 코로나바이러스 백신 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005015728A1 (de) | 2005-04-06 | 2006-10-12 | Robert Bosch Gmbh | Verbindungsvorrichtung für einen Antrieb sowie Verfahren zur Herstellung einer Verbindungsvorrichtung |
| WO2008095027A2 (en) * | 2007-01-30 | 2008-08-07 | Cedars-Sinai Medical Center | Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene |
| EP2181121A4 (en) | 2007-03-21 | 2012-07-11 | Id Biomedical Corp Quebec | CHIMÄRE ANTIGENE |
| HUE039908T2 (hu) | 2009-02-02 | 2019-02-28 | Glaxosmithkline Biologicals Sa | Majom adenovírusból származó nukleinsav- és aminosav-szekvenciák, azt tartalmazó vektorok és alkalmazásuk |
| WO2012021730A2 (en) | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
| WO2012089231A1 (en) | 2010-12-30 | 2012-07-05 | Okairòs Ag | Paramyxovirus vaccines |
| JP6091435B2 (ja) | 2011-02-22 | 2017-03-08 | カリフォルニア インスティチュート オブ テクノロジー | アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達 |
| WO2014078446A2 (en) | 2012-11-16 | 2014-05-22 | Allergan, Inc. | Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations |
| EP3154576A1 (en) * | 2014-06-13 | 2017-04-19 | GlaxoSmithKline Biologicals S.A. | Immunogenic combinations |
| WO2016198621A1 (en) | 2015-06-12 | 2016-12-15 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
| GB201513176D0 (en) | 2015-07-27 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
-
2018
- 2018-10-16 US US16/756,380 patent/US11859199B2/en active Active
- 2018-10-16 CA CA3079048A patent/CA3079048A1/en not_active Abandoned
- 2018-10-16 CN CN201880081339.5A patent/CN111527213A/zh not_active Withdrawn
- 2018-10-16 JP JP2020521363A patent/JP2020537526A/ja not_active Withdrawn
- 2018-10-16 WO PCT/EP2018/078212 patent/WO2019076882A1/en not_active Ceased
- 2018-10-16 MX MX2020003748A patent/MX2020003748A/es unknown
- 2018-10-16 EP EP18789095.9A patent/EP3697919A1/en not_active Withdrawn
- 2018-10-16 BR BR112020007008-4A patent/BR112020007008A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019076882A1 (en) | 2019-04-25 |
| CA3079048A1 (en) | 2019-04-25 |
| JP2020537526A (ja) | 2020-12-24 |
| US20210189422A1 (en) | 2021-06-24 |
| BR112020007008A2 (pt) | 2020-11-17 |
| CN111527213A (zh) | 2020-08-11 |
| US11859199B2 (en) | 2024-01-02 |
| EP3697919A1 (en) | 2020-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124213T1 (el) | Διαβιβαστες aav που περιεχουν γονιδιο κωδικοποιησης του παραγοντα viii | |
| CY1122833T1 (el) | Ογκολυτικος αδενοϊος που κωδικοποιει μια πρωτεϊνη β7 | |
| UA124343C2 (uk) | Капсиди аденоасоційованого вірусу і спосіб його використання | |
| CY1124921T1 (el) | Μεθοδοι για την εκχυλιση και τον καθαρισμο μη μετουσιωμενων πρωτεϊνων | |
| PH12019500068A1 (en) | Novel adeno-associated virus capsid proteins | |
| CY1122705T1 (el) | Αντιγονα, διαβιβαστες, συνθεσεις του ιου της ανθρωπινης ανοσοανεπαρκειας,και μεθοδοι χρησης τους | |
| WO2020257702A8 (en) | Rare earth element (ree)-binding proteins | |
| ES2652643T3 (es) | Péptidos terapéuticos y su uso contra la corea de Huntington | |
| EA202091054A1 (ru) | Слитые молекулы на основе антитела против pd-l1 и ил-7 | |
| EP3626274A3 (en) | Recombinant promoters and vectors for protein expression in liver and use thereof | |
| PY1546042A (es) | Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes | |
| MX2017004664A (es) | Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria. | |
| SA521422495B1 (ar) | مستضدات البروستاتا المستحدثة واستخداماتها | |
| CY1124727T1 (el) | Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων | |
| EP4462121A3 (en) | Recombinant glycosylated eculizumab and eculizumab variants | |
| CL2017000200A1 (es) | Célula huésped mejorada para producir proteinas | |
| MX2020011529A (es) | Un metodo para optimizar la expresion de anticuerpos. | |
| WO2020022898A3 (en) | Off-the-shelf cancer vaccines | |
| EP4041440A4 (en) | 2d material membrane with ionic selectivity | |
| MX2019008921A (es) | Adenovirus recombinante de transgenes múltiples. | |
| PH12020552222A1 (en) | Immunodominant proteins and fragments in multiple sclerosis | |
| EP4085064A4 (en) | LOOP PROTEINS THAT COMPRISE CELL-PENETRATING PEPTIDES | |
| RU2015102383A (ru) | ЭКСПРЕССИРУЮЩИЕ ПЛАЗМИДНЫЕ ВЕКТОРЫ pET32a(+)ASFV/p30e1 И pET32b(+)ASFV/p30e2 ДЛЯ СИНТЕЗА РЕКОМБИНАНТНЫХ БЕЛКОВ, СОСТОЯЩИХ ИЗ ФРАГМЕНТА p30 ВИРУСА АФРИКАНСКОЙ ЧУМЫ СВИНЕЙ, ТИОРЕДОКСИНА И ПОЛИГИСТИДИНОВЫХ УЧАСТКОВ | |
| WO2015057966A3 (en) | THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR MIDDLE EAST RESPIRATORY SYNDROME VIRUS (MERS CoV) | |
| EA201790241A1 (ru) | Эффективная селективность в отношении рекомбинантных белков |